The Canadian Prevention of Renal and Cardiovascular Endpoints Trial

NACompletedINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2008

Conditions
Chronic Kidney Disease
Interventions
OTHER

Combined CKD and CVD Prevention

Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone

OTHER

Cardiovascular Disease prevention

Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel

OTHER

Treatment of Chronic Kidney Disease complications

Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate

OTHER

Usual care

No prescribed intervention, just those that the patient's own family physician thought indicated

Trial Locations (5)

V6Z 1Y6

St. Paul's Hospital, Vancouver

A1B 3V6

Memorial University of Newfoundland, St. John's

B3H 1V8

Capitol District Health Authority, Halifax

N6A 4G3

London Health Sciences Centre, London

J4V 2H1

Charles LeMoyne Hospital, Greenfield Park

All Listed Sponsors
collaborator

Nova Scotia Health Authority

OTHER

collaborator

Hopital Charles Lemoyne

OTHER

collaborator

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

collaborator

University of British Columbia

OTHER

lead

Brendan Barrett

OTHER

NCT00231803 - The Canadian Prevention of Renal and Cardiovascular Endpoints Trial | Biotech Hunter | Biotech Hunter